title: Antinociception following implantation of mouse B16 melanoma cells in mouse and rat spinal cord.
abstract: B16 F1C29 melanoma cells, which are thought to contain and release catecholamines, were implanted in mouse and rat spinal subarachnoid space. B16 F1C29 cell implants augmented the antinociceptive effect of morphine in tail-flick test, and this interaction was blocked by either the alpha 2-adrenergic antagonist idazoxan or the opioid antagonist naloxone. B16 F1C29 cell implants also augmented the antinociceptive effect of the catecholamine re-uptake blocker desipramine. Substance P-induced biting and scratching behaviors were inhibited in mice receiving B16 F1C29 cell implants, and this effect of B16 F1C29 cell implants was blocked by the alpha 2-adrenergic antagonist idazoxan. Mice receiving B16 F1C29 cell implants showed tolerance to intrathecal administration of the alpha 2-adrenergic agonist UK 14304. These results suggest that B16 cell implant-induced antinociception was mediated by catecholamines secreted from the cell implants and acting at spinal alpha 2-adrenergic receptors. Spinal implantation of catecholamine-releasing cells may provide an alternative approach for the therapy of chronic intractable pain and a useful model to study alpha 2-adrenergic receptor tolerance.
authors.affiliation: Department of Pharmacology, University of Minnesota, Minneapolis, MN 55455 USA Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455 USA Department of Graduate Program in Neuroscience, University of Minnesota, Minneapolis, MN 55455 USA.
authors.forename: Hope H
authors.initials: HH
authors.lastname: Wu
authors.forename: Bruce R
authors.initials: BR
authors.lastname: Lester
authors.forename: Zhengqi
authors.initials: Z
authors.lastname: Sun
authors.forename: George L
authors.initials: GL
authors.lastname: Wilcox
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D000068438:Brimonidine Tartrate; D002395:Catecholamines / Q000502:physiology; D017690:Cell Transplantation; D003891:Desipramine / Q000494:pharmacology; D004146:Dioxanes / Q000494:pharmacology; D019329:Idazoxan; D007278:Injections, Spinal; D008297:Male; D008546:Melanoma, Experimental / Q000503:physiopathology*; D051379:Mice; D008813:Mice, Inbred ICR; D009020:Morphine / Q000008:administration & dosage / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology; D009368:Neoplasm Transplantation; D009619:Nociceptors / Q000502:physiology*; D017288:Pain Threshold / Q000187:drug effects; D011810:Quinoxalines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018341:Receptors, Adrenergic, alpha-2 / Q000187:drug effects; D013116:Spinal Cord / Q000503:physiopathology*; D013373:Substance P / Q000008:administration & dosage / Q000494:pharmacology; D016042:Transplantation, Heterotopic
chemical_list: D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D002395:Catecholamines; D004146:Dioxanes; D011810:Quinoxalines; D018341:Receptors, Adrenergic, alpha-2; D013373:Substance P; D009270:Naloxone; D000068438:Brimonidine Tartrate; D009020:Morphine; D003891:Desipramine; D019329:Idazoxan